普拉苏格勒与提卡格勒对接受药物侵入性策略的患者的冠状动脉微循环的影响 - 急性和短期结果
Rupesh Santosh Agrawal1, Jamal Yusuf1, Bhawna Mahajan2
1Department of Cardiology.
Coronary artery disease
|July 20, 2023
概括
与提卡格勒勒相比,prasugrel在ST升高心肌梗塞患者中显示出冠状动脉微循环的优异改善,这些患者正在接受药物侵入性皮肤穿透冠状动脉干预. 这导致了增强的心肌救援和改善的喷射分数与普拉苏格雷尔.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 提卡格勒和普拉苏格勒推用于接受皮肤冠状动脉干预 (PCI) 的ST升高心肌梗塞 (STEMI) 患者.
- 冲突的临床结果表明冠状动脉微循环的差异性影响,在药物侵入性PCI (pPCI) 中仍未研究.
研究的目的:
- 为了比较普拉苏格勒和蒂卡格勒勒对接受pPCI的STEMI患者冠状动脉微循环的影响.
- 评估二次结果,包括心脏病相关的动脉流量,左心室喷射率和出血并发症.
主要方法:
- 一个开放的随机试验,涉及240名STEMI患者,他们接受了血栓溶解,随后进行PCI.
- 患者被随机分配,在选择性PCI前2小时接受蒂卡格勒或普拉苏格勒.
- 使用心肌红色度 (MBG) 和心肌梗塞中纠正的血栓溶解 (cTFC) 评估了冠状动脉微循环;在6个月的随访中评估了射出分数和出血事件.
主要成果:
- 与提卡格勒相比,普拉苏格勒的MBG 3级显著更高 (50.86%与33.89%) 和较低的cTFC (17.14与19.3).
- 使用普拉苏格勒,喷射分数的改善显著更大 (10.29% ± 15.2 vs 4.66% ± 13.5).
- 6个月后发生的出血事件在两组之间是相似的 (11.86%对6.9%).
结论:
- 与提卡格勒勒相比,普拉苏格勒在接受pPCI的STEMI患者中显著改善了冠状动脉微循环.
- 这种增强的微循环功能与普拉苏格勒可能有助于改善心肌救援和更好的左心室功能.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
Coronary Artery Disease V: Interprofessional Care
10
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
10
Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
567
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
567


